Elevance Health Q3 2024 Adj. EPS $8.37 Misses $9.66 Estimate, Sales $44.719B Beat $43.330B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elevance Health reported its Q3 2024 financial results, with adjusted EPS of $8.37, missing the estimate of $9.66. However, the company exceeded sales expectations, reporting $44.719 billion compared to the estimated $43.330 billion.
October 17, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Elevance Health's Q3 2024 earnings report shows a mixed performance with EPS missing estimates but sales exceeding expectations.
The mixed results, with EPS missing but sales beating expectations, suggest a neutral short-term impact on Elevance Health's stock. Investors may weigh the earnings miss against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100